Abstract: The present application relates to metal-organic framework (MOF) nanoparticles, in particular, coated MOF nanoparticles, methods of manufacturing said coated MOF nanoparticles, and uses of said coated MOF nanoparticles.

Abstract: A monolithic metal-organic framework (MOF) composite body is disclosed, comprising: MOF crystallites adhered to each other via a binder comprising MOF; and at least 0.15 vol % nanoparticles encapsulated in the MOF body. The nanoparticles have an average particle size corresponding to an average particle diameter in the range 3-200 nm. The nanoparticles may have photocatalytic activity. The MOF composite body is of use for treating water containing an organic dye, the photocatalytic reaction supported by the photocatalytic nanoparticles being a degradation reaction of the organic dye.

Abstract: The present invention provides a covalent-organic framework (COF) body, populations of such bodies, a method for manufacturing a covalent-organic framework (COF) body, and (a) a gas storage system or a gas separation system comprising a gas storage vessel and a population of such COF bodies. The COF body comprises a plurality of primary COF particles, some or all of the primary COF particles being agglomerated as COF agglomerates. The average diameter of the primary COF particles is between nm and 120 nm, and the average diameter of the agglomerates is larger than the average diameter of the primary COF particles and between 15 nm and 250 nm. By careful control over particle size distribution during the formation of the COF material, it is possible (b) to form COF materials into high bulk density shapes and forms which are industrially useful and practical without losing sorbent performance.

Abstract: The invention provides an amorphous metal-organic framework for use in methods of treatment. The amorphous metal-organic framework may hold a component for delivery. The amorphous metal-organic framework is obtained or is obtainable by amorphization of a crystalline amorphous metal-organic framework holding the component. The amorphous metal-organic framework may be a zirconium-containing or a bismuth-containing metal-organic framework, such as a framework having arylcarboxylate ligands, such as benzenedicarboxylate ligands.

Abstract: A monolithic metal-organic framework (MOF) composite body is disclosed, comprising: MOF crystallites adhered to each other via a binder comprising MOF; and at least 0.15 vol % nanoparticles encapsulated in the MOF body. The nanoparticles have an average particle size corresponding to an average particle diameter in the range 3-200 nm. The nanoparticles may have photocatalytic activity. The MOF composite body is of use for treating water containing an organic dye, the photocatalytic reaction supported by the photocatalytic nanoparticles being a degradation reaction of the organic dye.

Abstract: The invention provides an amorphous metal-organic framework for use in methods of treatment. The amorphous metal-organic framework may hold a component for delivery. The amorphous metal-organic framework is obtained or is obtainable by amorphization of a crystalline amorphous metal-organic framework holding the component. The amorphous metal-organic framework may be a zirconium-containing or a bismuth-containing metal-organic framework, such as a framework having arylcarboxylate ligands, such as benzenedicarboxylate ligands.

Abstract: A metal-organic framework (MOF) body that includes MOF crystallites adhered to each other via a MOF binder is provided. In one embodiment, the body consists of: MOF crystallites; a MOF binder which binds the crystallites together in the body; optionally, residual solvent; and optionally, one or more additives, where the additives are present at a level of not more than 10% by mass. The MOF binder may have substantially the same composition as the MOF crystallites. Alternatively, the MOF binder may have a different composition to the MOF crystallites.

Abstract: Disclosed is a metal-organic framework (MOF) body comprising MOF crystallites adhered to each other via a MOF binder. In one embodiment, the body consists of: MOF crystallites; a MOF binder which binds the crystallites together in the body; optionally, residual solvent; and optionally, one or more additives, wherein the additives are present at a level of not more than 10% by mass. The MOF binder may have substantially the same composition as the MOF crystallites. Alternatively, the MOF binder may have a different composition to the MOF crystallites.